HF
MRSN

HRT Financial’s Mersana Therapeutics MRSN Stock Holding History

HRT Financial’s Portfolio MRSN Stock Details MRSN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-3,735
Closed -$27K – 3373
2025
Q2 		$27K Buy
3,735
+1,875
+101% +$16.5K ﹤0.01% 2367
2025
Q1 		$16K Buy
+1,860
New +$28.7K ﹤0.01% 2321
2024
Q3 		– Sell
-10,388
Closed -$521K – 2867
2024
Q2 		$521K Buy
+10,388
New +$751K ﹤0.01% 1286
2024
Q1 		– Sell
-4,233
Closed -$245K – 2801
2023
Q4 		$245K Buy
4,233
+1,666
+65% +$67K ﹤0.01% 1706
2023
Q3 		$81K Buy
+2,567
New +$122K ﹤0.01% 1967
2023
Q1 		– Sell
-448
Closed -$65K – 2931
2022
Q4 		$65K Sell
448
-4,065
-90% -$687K ﹤0.01% 2101
2022
Q3 		$762K Buy
+4,513
New +$733K 0.01% 1104
2022
Q2 		– Sell
-7,043
Closed -$702K – 3412
2022
Q1 		$702K Buy
7,043
+2,366
+51% +$276K 0.01% 1381
2021
Q4 		$727K Buy
+4,677
New +$910K ﹤0.01% 1474
2021
Q2 		– Sell
-1,276
Closed -$516K – 3265
2021
Q1 		$516K Buy
+1,276
New +$619K 0.01% 1752

Other funds holding MRSN

NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return
AV
Alamea Verwaltungs Edison, New Jersey $125M AUM 27.56% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $27.9B AUM 51.18% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $962M AUM 524.64% 1-Year Est. Return
6CM
683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

HRT Financial's MRSN Position: Q3 2025 in Review

HRT Financial sold out of Mersana Therapeutics (MRSN) in Q3 2025, closing a stake of 3,735 shares — an estimated $27K sold.

HRT Financial first reported a position in MRSN in Q1 2021 and held it in 10 quarters. The position peaked at $762K in Q3 2022. 49 funds tracked by Wall St. Rank hold MRSN as of Q3 2025.

  • HRT Financial reported no remaining Mersana Therapeutics position as of Q3 2025 after selling out during the quarter.
  • HRT Financial sold 3,735 Mersana Therapeutics shares in Q3 2025, an estimated $27K.
  • HRT Financial first reported a position in Mersana Therapeutics in Q1 2021 and held it in 10 quarters.
  • HRT Financial's Mersana Therapeutics position peaked at $762K in Q3 2022.
  • 49 funds tracked by Wall St. Rank held Mersana Therapeutics as of Q3 2025.

Based on HRT Financial's 13F filing for Q3 2025, filed 14 Nov 2025.